Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability and pharmacokinetics of single and repeat doses of the dry powder formulation of GSK2269557 in healthy subjects; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK2269557

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED